{"id":"NCT01350973","sponsor":"Takeda","briefTitle":"Efficacy of TAK-085 in Participants With Hypertriglyceridemia","officialTitle":"A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2011-05-10","resultsPosted":"2016-09-20","lastUpdate":"2016-09-20"},"enrollment":611,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertriglyceridemia"],"interventions":[{"type":"DRUG","name":"Omega-3-acid ethyl esters 90 (TAK-085)","otherNames":["LOVAZA","Omacor"]},{"type":"DRUG","name":"Eicosapentaenoic acid-ethyl (EPA-E)","otherNames":["AtheropanÂ®"]}],"arms":[{"label":"TAK-085 2 g","type":"EXPERIMENTAL"},{"label":"TAK-085 4 g","type":"EXPERIMENTAL"},{"label":"EPA-E 1.8 g","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to determine the efficacy and safety of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.","primaryOutcome":{"measure":"Percent Change From Baseline in Triglyceride Level at the Final Visit","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"TAK-085 2 g","deltaMin":-10.93,"sd":1.6434},{"arm":"TAK-085 4 g","deltaMin":-22.65,"sd":1.6238},{"arm":"EPA-E 1.8 g","deltaMin":-11.3,"sd":1.6807}],"pValues":[{"comp":"OG000 vs OG002","p":"0.8760"},{"comp":"OG001 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":205},"commonTop":["Nasopharyngitis"]}}